Working to transform lives through the development of innovative IL-1β therapies
At Avalo, we’re 100% focused on developing treatments for immune-mediated inflammatory diseases with large unmet needs that affect millions worldwide. Our strategy is to develop medicines that target the IL-1β pathway, which is a central driver of the inflammatory process. Our lead asset, AVTX-009, is an anti-IL-1β monoclonal antibody currently being studied in a Phase 2 trial in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1–4% of the population globally.1 AVTX-009 has the potential to treat multiple other immune mediated diseases, and we are exploring its utility in a number of additional indications.
Our mission
To transform lives with novel therapeutics that realize the promise of best-in-class and best-in-disease medicines.
Our vision
Driven by compassion and science, we develop and commercialize targeted therapeutics for people living with diseases with significant unmet clinical needs.
Avalo and the enso circle
Our name and circular mark hold special meaning for us. The name Avalo is tied to the compassion we feel for those living with chronic disease—compassion that drives us to work tirelessly towards better solutions. The open circle in our logo, called an “enso circle,” is a symbol of the strength, creativity, minimalism, and growth we continually strive to embody. It also reminds us that our mission won’t be complete until we’ve addressed the remaining unmet needs of those struggling with inflammatory diseases.